ArticleiScience2021
Modeling SARS-CoV-2 infection and its individual differences with ACE2-expressing human iPS cells.
Article in iScience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Human-induced pluripotent stem cell-derived hepatocyte platform in modeling of SARS-CoV-2 infection.JGH open : an open access journal of gastroenterology and hepatology · 2024Article
- Morphological analysis for two types of viral particles in vacuoles of SARS-CoV-2-infected cells.Medical molecular morphology · 2024Article
- The cytotoxicity of gefitinib on patient‑derived induced pluripotent stem cells reflects gefitinib‑induced liver injury in the clinical setting.Oncology letters · 2023Article
- Article
- SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression.Science advances · 2022Article
- Article
- Evidence of Infection of Human Embryonic Stem Cells by SARS-CoV-2.Frontiers in cellular and infection microbiology · 2022Article
- Dual inhibition of TMPRSS2 and Cathepsin Bprevents SARS-CoV-2 infection in iPS cells.Molecular therapy. Nucleic acids · 2021Article
- SARS-CoV-2 research using human pluripotent stem cells and organoids.Stem cells translational medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic differences are a primary reason for differences in the susceptibility and severity of COVID-19. As induced pluripotent stem (iPS) cells maintain the genetic information of the donor, they can be used to model individual differences in SARS-CoV-2 infection
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.